دورية أكاديمية
Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trial.
| العنوان: | Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trial. |
|---|---|
| المؤلفون: | Naik HB; Department of Dermatology, University of California, San Francisco, California. Electronic address: Haley.Naik@ucsf.edu., Pichard DC; Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland., Schwartz DM; Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland., O'Brien M; Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland., Masciocchi M; Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland., Thompson J; Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland., Sen HN; Clinical and Translational Immunology Unit, Laboratory of Immunology, National Eye Institute, Bethesda, Maryland., Steinberg SM; Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Mitchell SA; Division of Cancer Control and Population Sciences, Outcomes Research Branch, National Cancer Institute, Rockville, Maryland., de Jesus AA; Translational Autoinflammatory Diseases Section (TADS), LCIM, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland., McCalmont TH; Department of Dermatology, University of California, San Francisco, California; Department of Pathology, University of California, San Francisco, California., Dey A; Section of Inflammation and Cardiovascular Diseases, National Institute of Heart, Lung and Blood Diseases, Bethesda, Maryland., Rosenstein RK; Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland., Deng Z; Biodata Mining and Discovery Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland., Goldbach-Mansky R; Translational Autoinflammatory Diseases Section (TADS), LCIM, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland., Mehta NN; Section of Inflammation and Cardiovascular Diseases, National Institute of Heart, Lung and Blood Diseases, Bethesda, Maryland., Cowen EW; Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland. |
| المصدر: | Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2022 Dec; Vol. 87 (6), pp. 1380-1383. Date of Electronic Publication: 2022 Sep 16. |
| نوع المنشور: | Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: St. Louis, Mo., Mosby |
| مواضيع طبية MeSH: | Psoriasis*/drug therapy , Dermatologic Agents*/therapeutic use , Skin Diseases, Vesiculobullous*/drug therapy, Humans ; Interleukin 1 Receptor Antagonist Protein/adverse effects |
| مستخلص: | Competing Interests: Conflicts of interest HBN has received grant support from AbbVie, consulting fees from 23andMe, AbbVie, and DAVA Oncology, and advisory board fees from Boehringer Ingelheim, all related to hidradenitis suppurativa. DMS and HBN have received grant support from the National Psoriasis Foundation. RGM has received grant support from SOBI, Novartis, Regeneron, and Lilly under US Federal Government Cooperative Research and Development Agreements. DCP, MO, MM, JT, HNS, SMS, SM, AADJ, THM, AD, RKR, ZD, NNM and EWC have no conflicts of interest to report. |
| References: | Dermatology. 2015;230(1):27-33. (PMID: 25613671) Ann Rheum Dis. 2016 May;75(5):811-8. (PMID: 26269398) J Allergy Clin Immunol. 2019 Mar;143(3):1021-1026. (PMID: 30036598) Br J Dermatol. 2021 Aug 19;:. (PMID: 34411292) |
| معلومات مُعتمدة: | K23 AR074531 United States AR NIAMS NIH HHS; Z01 SC007202 United States ImNIH Intramural NIH HHS; ZIA AR041228 United States ImNIH Intramural NIH HHS; ZIA BC011550 United States ImNIH Intramural NIH HHS |
| المشرفين على المادة: | 0 (Interleukin 1 Receptor Antagonist Protein) 0 (Dermatologic Agents) |
| تواريخ الأحداث: | Date Created: 20220918 Date Completed: 20221206 Latest Revision: 20231126 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10673680 |
| DOI: | 10.1016/j.jaad.2022.07.065 |
| PMID: | 36116584 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1097-6787 |
|---|---|
| DOI: | 10.1016/j.jaad.2022.07.065 |